Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Novasep S.A.. (5/3/18). "Press Release: Novasep Invests €10M in “SeneFill”, Its New Facility for Commercial Aseptic Fill & Finish Operations". Lyon.

Organisation Organisation Novasep, Seneffe (BE)
  Group Novasep (Group)
Products Product contract manufacturing (biologicals)
  Product 2 viral vector_o
Persons Person Spagnol, Michel (Novasep 201306– CEO before Shasun + Rhodia)
  Person 2 Bléhaut, Jean (Novasep 201509 Chief Innovation Officer)

This facility, located in Seneffe (Belgium), will strengthen Novasep’s drug product services for mAbs, viral vectors and other low volume biopharmaceuticals

Novasep, a leading supplier of services and technologies for the life sciences industry, announces a €10M investment in a commercial fill & finish facility for viral vectors, mAbs and other low-volume biologics. The facility will be located in Seneffe (Belgium) and will be operational in H2 2019.

Fill & finish operations are critical to ensure the safety and efficacy of a drug. This step involves filling biologics into containers under aseptic conditions and is the final part of the biopharmaceutical manufacturing process, after upstream bioprocessing (cell culture) and downstream processing (purification).

The new Novasep plant will feature a fill & finish suite with state of the art filling equipment and isolators. It will deliver up to 10 000 vials per session, with 2 to 3 sessions per week. In line with its strategic development plan, the investment will allow Novasep to respond to the strong market demand for orphan and targeted biopharmaceutical drugs as clinical pipelines mature.

This project is part of Novasep’s Rise-2 strategic growth cycle. It complements a €27M investment in a new commercial scale viral vector production facility in Seneffe (Belgium) that will be fully qualified by Q1 2019, and a €17M investment in a dedicated cGMP clinical scale mAb production facility that will be located in Pompey (France) and will be commissioned in H2 2019.

“The trend towards targeted therapies has created a growing need for specialized capacities,” said Jean Bléhaut, President of Novasep’s Manufacturing Solutions Business Unit, “In response, Novasep has launched a series of major projects to boost its biomanufacturing services for selected types of drug substances and Fill & Finish activities.”

Dr. Michel Spagnol, Novasep’s Chairman and CEO,added: “After the €17M investment in our mAb production facility and the €27M investment in gene therapy production, this is the third investment that we announce to support the strong development of innovative therapies. With this third investment, Novasep furthers its engagement to the RISE-2 strategic plan aimed at doubling the company’s size by 2022.”

For press information, click here:

Press contact:

Laure Saloin
Communication Project Manager
+33 7 77 94 37 52

Press release - About Novasep

About Novasep
Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules and fine chemicals. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries.

A propos de Novasep
Novasep fournit des solutions économiques pour la production durable de molécules pour les sciences de la vie et la chimie fine. L’offre globale de Novasep comprend des services de développement de procédés, des équipements et des systèmes clés en main de purification, des services de fabrication sous contrat ainsi que des molécules complexes actives s’adressant aux secteurs pharmaceutique, biopharmaceutique et de la chimie fine ainsi qu’aux marchés des ingrédients alimentaires et fonctionnels, des industries de matières premières issues de fermentation et de synthèse chimique.

Über Novasep
Novasep ist ein führender Anbieter von wirtschaftlichen und nachhaltigen Lösungen für die Herstellung von Molekülen für Life Sciences und Feinchemieindustrie. Das umfassende Angebot von Novasep beinhaltet die Verfahrensentwicklung im Kundenauftrag, schlüsselfertige Aufreinigungsanlagen und -systeme, Auftragsherstellung sowie komplexe Wirkstoffmoleküle für Pharma, Biopharma und Feinchemie sowie die Märkte Lebensmittelzusatzstoffe, funktionale Inhaltsstoffe, Fermentierung und chemische Commodities.

Press Contact
Laure Saloin
Communication Project Manager - Corporate Branding & Social Media
+33 (0)7 77 94 37 52

Record changed: 2018-05-31


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Novasep (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top